NDAINJECTIONINJECTABLE
Approved
Dec 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
INTRALIPID 30% (i. v. fat emulsion) by Fresenius Kabi is clinical pharmacology intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. First approved in 1993.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Intralipid 30% is an intravenous fat emulsion indicated for parenteral nutrition support in patients requiring caloric supplementation when oral or enteral feeding is not feasible. It supplies essential fatty acids and energy substrate, preventing essential fatty acid deficiency (EFAD) while being metabolized as a source of heat production and oxygen consumption.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on margin defense and cost management rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Intralipid is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the…
Pharmacologic Class:
Lipid Emulsion
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities on Intralipid are limited and defensive in nature, as the product approaches loss of exclusivity in a mature market. Roles available focus on margin protection, hospital relationships, and regulatory compliance rather than growth or innovation.
Brand Manager
Worked on INTRALIPID 30% at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.